Sutimlimab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric/humanized hybrid |
| Target | complement component 1s |
| Clinical data | |
| Trade names | Enjaymo |
| Other names | BIVV009, sutimlimab-jome |
| License data |
|
| Routes of administration | Intravenous infusion |
| Drug class | Complement inhibitor |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
Sutimlimab, sold under the brand name Enjaymo, is a monoclonal antibody that is used to treat adults with cold agglutinin disease (CAD). It is given by intravenous infusion. Sutimlimab prevents complement-enhanced activation of autoimmune human B cells in vitro.
The most common side effects include headache, high blood pressure, urinary tract infection (infection of the structures that carry urine), upper respiratory tract infection (nose and throat infection), nasopharyngitis (inflammation of the nose and throat), nausea, abdominal pain, infusion-related reactions and cyanosis (bluish discoloration of hands and feet in response to cold and stress).
This medication is being developed by Bioverativ, a Sanofi company. Sutimlimab was approved for medical use in the United States in February 2022, and in the European Union in November 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.